Research programme:CD3 targeting bispecific antibodies - iBio Inc
Latest Information Update: 23 May 2023
Price :
$50 *
At a glance
- Originator iBio Inc
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer; Immunological disorders
Most Recent Events
- 19 Apr 2023 Early research in Cancer in USA (Parenteral) prior to April 2023
- 04 Apr 2023 Early research in Immunological disorders in USA (Parenteral) prior to April 2023